Tue, Feb 25, 10:08 PM (61 days ago)
Integra LifeSciences Holdings Corp (IART) reported 2024 net revenues of $1.61B, with its Codman Specialty Surgical segment generating about $1.14B and Tissue Technologies around $467M. The company recorded a net loss of $6.9M (or $0.09 per diluted share) versus a net income of $67.7M in 2023, impacted by operational quality issues, restructuring costs—including integration expenses from the recent Acclarent acquisition—and expenses associated with a Boston facility recall and transition to a new Braintree site expected to become operational in H1 2026. Operating expenses rose by 10.4% due to higher SG&A, R&D, and intangible asset amortization. The report highlights progress on new product approvals (e.g., PMA for DuraSorb), global growth initiatives in neurosurgery, ENT, and regenerative care, and ongoing regulatory and market risks including currency and interest rate exposures.